Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pim-2 shRNA
- Development stage
- Preclinical
- Lead developer
- North Carolina Central University
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intraperitoneal, Intravenous, Parenteral
01
Overview
Pim-2 shRNA is a short hairpin RNA designed to silence the expression of the **Pim-2** proto-oncogene, a member of the proviral insertion site in Moloney murine leukemia virus (Pim) family of serine/threonine kinases. Pim-2 is known to be aberrantly expressed in various malignancies, including pancreatic ductal adenocarcinoma (PDAC), where it promotes cell survival and proliferation by phosphorylating downstream targets like 4EBP-1 and inhibiting apoptosis. By delivering shRNA specific to the Pim-2 sequence, researchers can induce the degradation of Pim-2 mRNA via the RNA interference (RNAi) machinery, effectively knocking down protein levels. Preclinical studies, such as those conducted by North Carolina Central University and Jasco Pharmaceuticals, have demonstrated that Pim-2 shRNA can significantly decrease cell viability and anchorage-independent growth in pancreatic cancer models, validating Pim-2 as a potential therapeutic target.
- Other names
- Pim-2 short hairpin RNAPim2 short hairpin RNAPim 2 short hairpin RNA
02
Targets
Serine/threonine-protein kinase pim-2 (PIM2) mRNA
Beyond the preview
Go deeper on Pim-2 shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pim-2 shRNA.